Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07101601 | Study of DM5167 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 58 | DIGMBIOINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06305312 |
| recruiting |
| N/A |
| 1,450 |
| University of UtahOTHER |
| 1 |
| Aug 1, 2025 |
| clinicaltrials |
| NCT06358625 | Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer(CRANIUM) | recruiting | — | 120 | Center Eugene MarquisOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06462963 | OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)(SPRINT) | recruiting | N/A | 302 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Aug 1, 2025 | clinicaltrials |
| NCT07096180 | Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer | recruiting | — | 200 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07020780 | 5 fr Ultrahypofractionated WBI and SIB for Breast Cancer With Unfavorable Characteristics | recruiting | N/A | 458 | IRCCS San RaffaeleOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05181033 | Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | recruiting | Phase 2 | 120 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05804578 | Using a Blood Test to Monitor Metastatic Breast Cancer Treatment(BEACON) | recruiting | — | 150 | Dr. Christopher MuellerOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06174363 | Analgesic Efficacy of Maxigesic in Breast Cancer Surgery | recruiting | N/A | 84 | Yonsei UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07073755 | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | recruiting | — | 200 | Hunan Cancer HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07071272 | Non-inferiority Study of Contrast-enhanced Digital Mammography (CEDM) vs Magnetic Resonance Imaging (MRI) in Terms of Diagnostic Accuracy in Patients Undergoing Preoperative Staging of Established Invasive Breast Cancer(CEDM-VR) | recruiting | N/A | 216 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05658341 | Program of Physical Activity, Nutrition and Supportive to Improve the Quality of Life of Breast Cancer Survivors(ADA) | recruiting | N/A | 160 | Siel BleuOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07059104 | Implant-based Breast Reconstruction in Post-bariatric Women - a Registry-based National Study | recruiting | — | 20,000 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07046689 | PET/CT for Trop2 ADC Response Evaluation Cancers | recruiting | — | 50 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07066280 | Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer | recruiting | Phase 3 | 326 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07066917 | Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer(PANDORA) | recruiting | — | 150 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06033287 | Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. | recruiting | — | 300 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05722795 | Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)(I-CONIC) | recruiting | N/A | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07057427 | Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 812 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05396612 | Role of the Immune Environment in Response to Therapy in Breast Cancer | recruiting | — | 300 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06792721 | MEASUREMENT OF CIRCULATING MUTATION BURDEN(cRISK) | recruiting | — | 30 | Centre Francois BaclesseOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT04714463 | Effects of Expectations and Body Image in Breast Reconstruction | recruiting | — | 500 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05222100 | Effect of Breast Implants om Mammography Screening | recruiting | — | 2,500 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05233891 | Validation of Scales in Reconstructive Breast Surgery(ValPlast) | recruiting | — | 500 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05363189 | Optimizing Postoperative Recovery After Breast Reconstruction With Autologous Tissue (BestDIEP)(BestDIEP) | recruiting | — | 380 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06195865 | Autologous vs. Implant-based Breast Reconstruction(GoBreast II) | recruiting | N/A | 250 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06402435 | SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer | recruiting | Phase 2 | 50 | Hubei Cancer HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047495 | Personalization of External Beam Radiation Therapy in Localised Tumours(MINIONS) | recruiting | — | 35 | European Institute of OncologyOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05896865 | Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer(RADAPT-N3) | recruiting | N/A | 120 | Samsung Medical CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05907681 | Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M) | recruiting | — | 400 | Samsung Medical CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05933733 | Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer(SALT-LRR) | recruiting | — | 190 | Samsung Medical CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06308029 | Effectiveness of an eHealth Self-management Support Program for Persistent Pain After Breast Cancer Treatment(PECAN) | recruiting | N/A | 270 | Universiteit AntwerpenOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06500208 | Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06839001 | CRYoablation for Small Tumors As Local Treatment - SIX Trial(CRYSTAL - SIX) | recruiting | Phase 3 | 750 | Hospital do CoracaoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06665178 | Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | recruiting | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07003074 | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 642 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07030569 | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study(RADIOSPHER2) | recruiting | — | 500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06383767 | A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | recruiting | Phase 3 | 378 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06568692 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 90 | Processa PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07021846 | Dose Escalated Concomitant Boost Radiotherapy for Early Breast Cancer(DEBoRa) | recruiting | N/A | 132 | Fondazione Policlinico Universitario Campus Bio-MedicoOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07021911 | Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer(COMBaRT) | recruiting | — | 300 | Fondazione Policlinico Universitario Campus Bio-MedicoOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2025source: clinicaltrials